Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(145 produits)
- Bcr-Abl(102 produits)
- EGFR(572 produits)
- FAK(72 produits)
- FLT(92 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(170 produits)
- JAK(245 produits)
- PDGFR(126 produits)
- RAAS(86 produits)
- Src(78 produits)
- Syk(38 produits)
- Thrombine(47 produits)
- VDA(2 produits)
- VEGFR(268 produits)
Affichez 6 plus de sous-catégories
1414 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Syk Inhibitor II
CAS :<p>Syk inhibitor II, a cell-permeable, ATP-competitive, pyrimidine-carboxamide compound, selectively and reversibly inhibits Syk (IC50 = 41 nM).</p>Formule :C14H15F3N6ODegré de pureté :97.63%Couleur et forme :SolidMasse moléculaire :340.3BIBF 1202
CAS :<p>BIBF 1202 is a VEGFR2 kinase inhibitor (IC50 = 62 nM).</p>Formule :C30H31N5O4Degré de pureté :98.04%Couleur et forme :SolidMasse moléculaire :525.6Canertinib dihydrochloride
CAS :<p>Canertinib dihydrochloride (PD-183805 dihydrochloride) is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and</p>Formule :C24H27Cl3FN5O3Degré de pureté :99.13% - >99.99%Couleur et forme :SolidMasse moléculaire :558.86BMS-690514
CAS :<p>BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR. It has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.</p>Formule :C19H24N6O2Degré de pureté :99.08%Couleur et forme :SolidMasse moléculaire :368.43Methyl 6-[[[(2-Chloroethyl)amino]carbonyl]amino]-6-deoxy-α-D-glucopyranoside
CAS :Produit contrôléFormule :C10H19ClN2O6Couleur et forme :NeatMasse moléculaire :298.72(5E)-5-(4-Hydroxybenzylidene)-1,3-thiazolidine-2,4-dione
CAS :Produit contrôlé<p>Applications 5-[(4-Hydroxyphenyl)methylene]-2,4-thiazolidinedione is a 5-Benzylidene-2,4-thiazolidenedione derivative designed as inhibitors of angiogenesis targeting VEGFR-2. Also, it is an intermediate used in the synthesis of MSDC 0602 (M755420), which is an analogue of thiazolidinediones, exhibits low affinity for binding and activation of peroxisome proliferator-activated receptor γ (PPARγ). Thiazolidinediones are effective insulin-sensitizing drugs for treating various metabolic and inflammatory diseases.<br>References Bhanushali, U., et al.: Bioorg. Chem., 67, 139-147 (2016); Chen, Z., et al.: J. Biol. Chem. 287, 23537 (2012); Fukunaga, T., et al.: J. Bone Miner. Res., 30, 508 (2015)<br></p>Formule :C10H7NO3SCouleur et forme :NeatMasse moléculaire :221.23Fidasimtamab
CAS :<p>Fidasimtamab, a recombinant human IgG1 bispecific antibody, targets both HER2 and PD-1, bridging T cells and tumor cells to modulate immune responses.</p>Degré de pureté :95% - 95%Couleur et forme :LiquidDepatuxizumab
CAS :<p>Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, inhibit tumor growth,GBM,SCCHN.</p>Degré de pureté :95%Couleur et forme :LiquidBafisontamab
CAS :<p>Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].</p>Couleur et forme :LiquidFaricimab
CAS :<p>Faricimab,Bispecific antibody targeting Ang-2/VEGF-A. Prevents retinal I/R injury. Improves vision in w-AMD, DME, RVO.</p>Degré de pureté :95% - 95%Couleur et forme :LiquidZalutumumab
CAS :<p>Zalutumumab is a high-affinity fully human monoclonal antibody ,the extracellular domain of the EGFR squamous cell carcinoma of the head and neck (SCCHN).</p>Degré de pureté :95%Couleur et forme :LiquidSolrikitug
CAS :<p>Solrikitug,Anti-CRLF2 humanized IgG1κ monoclonal antibody.</p>Degré de pureté :95%Couleur et forme :LiquidPonezumab
CAS :<p>Ponezumab (PF-04360365), a humanized IgG2 antibody, lowers Aβ in the CNS & boosts mice memory. Used in Alzheimer's research.</p>Couleur et forme :LiquidIvonescimab
CAS :<p>Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, NSCLC).</p>Degré de pureté :95% - 95%Couleur et forme :LiquidVanucizumab
CAS :<p>Vanucizumab is a bispecific humanised monoclonal antibody that simultaneously inhibits the receptor interactions of VEGF-A and Angiopoietin-2 (Ang-2)</p>Degré de pureté :95%Couleur et forme :LiquidIzalontamab
CAS :<p>Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR×EGFR homodimers and EGFR×HER3 heterodimers.</p>Degré de pureté :95%+ - 95%+Couleur et forme :LiquidTovetumab
CAS :<p>Tovetumab (MEDI-575) is an anti-PDGFRα mAb inhibiting its signaling, in trials for glioblastoma and NSCLC.</p>Degré de pureté :95%Couleur et forme :LiquidAnti-Mouse VEGFR-2 Antibody (DC101)
<p>Anti-Mouse VEGFR-2 Antibody (DC101) is a rat-derived monoclonal antibody against mouse VEGFR2/KDR/Flk-1, serving as a mouse analogue of ramucirumab.</p>Degré de pureté :99%Couleur et forme :Odour LiquidDilpacimab
CAS :<p>Dilpacimab (ABT165) is a dual-variable antibody that targets DLL4 and VEGF pathways, showing potential in cancer research by blocking angiogenesis and Notch.</p>Degré de pureté :95% - 95%Couleur et forme :LiquidBecotatug
CAS :<p>Becotatug (JMT-101) is an IgG1 antibody that targets EGFR and can be conjugated to Afatinib and Osimertinib, functioning as a synthetic antibody-drug conjugate</p>Degré de pureté :95% - 95%Couleur et forme :LiquidElgemtumab
CAS :<p>Elgemtumab (LJM716) is a fully humanised monoclonal antibody targeting HER3/ERBB3, acting as an antagonist to block HER3/Akt phosphorylation antitumour.</p>Degré de pureté :95%Couleur et forme :LiquidZanidatamab
CAS :<p>Zanidatamab (ZW25) is a bispecific, humanized monoclonal antibody that targets two distinct epitopes (ECD2 and ECD4) of the HER2 receptor, exhibiting anti-tumor</p>Couleur et forme :LiquidTarcocimab
CAS :<p>Tarcocimab (OG1953) is a humanized IgG1 monoclonal antibody targeting VEGFA, researched for RVO and wet AMD.</p>Couleur et forme :LiquidSerclutamab
CAS :<p>Serclutamab, a humanized chimeric monoclonal antibody of the IgG1-κ isotype, selectively targets the epidermal growth factor receptor (EGFR).</p>Degré de pureté :98%Couleur et forme :LiquidFutuximab
CAS :<p>Futuximab, a chimeric monoclonal antibody, targets distinct epitopes on the epidermal growth factor receptor (EGFR), exhibiting antineoplastic activity [1].</p>Degré de pureté :95% - 95%Couleur et forme :LiquidImgatuzumab
CAS :<p>Imgatuzumab (RG 7160) is a humanized anti-EGFR monoclonal antibody and immunomodulator for cancer research.</p>Couleur et forme :LiquidMasse moléculaire :145.0 (kDa)Anbenitamab
CAS :<p>Anbenitamab (KN-026) is a bispecific HER2 antibody for metastatic breast cancer research, blocking HER2 pathways and mediating ADCC.</p>Couleur et forme :LiquidIbrutinib-d5
CAS :<p>Ibrutinib D5 is a deuterium-labeled Ibrutinib. Ibrutinib is an irreversible Btk inhibitor.</p>Formule :C25H24N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :445.53Dasatinib-d8
CAS :<p>Dasatinib D8 is deuterium-labeled dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.</p>Formule :C22H26ClN7O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :496.06Erlotinib mesylate
CAS :<p>Erlotinib: reversible inhibitor binding to ATP site of epidermal growth factor receptor.</p>Formule :C23H27N3O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :489.54MAPK-IN-2
<p>MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell</p>Formule :C20H11Cl2N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.23ALK5-IN-79
CAS :<p>ALK5-IN-79 (compound 57), an ALK inhibitor, exhibits anticancer activity by inhibiting the TGF-β1/SMAD signaling pathway. It effectively reduces the production of extracellular matrix (ECM) and collagen deposition. Moreover, ALK5-IN-79 demonstrates satisfactory pharmacokinetic (PK) properties and favorable in vivo tolerance.</p>Formule :C23H27N7OCouleur et forme :SolidMasse moléculaire :417.51(3S,4S)-Tofacitinib
CAS :<p>(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.</p>Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37ZM39923
CAS :<p>ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).</p>Formule :C23H25NODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :331.45EGFR-IN-117
CAS :<p>EGFR-IN-117 (Compound 8h) exhibits inhibitory activity against EGFR mutations, specifically targeting the tumor environment and inducing apoptosis in cancer cells. This compound effectively inhibits the proliferation of H1975, PC-9, and mutant EGFR cells including BaF3-EGFRL858R/T790M/C797S and BaF3–C797S/Del19/T790M, with IC50 values of 13 nM, 19 nM, 1.2 nM, and 1.3 nM respectively. Additionally, EGFR-IN-117 demonstrates anti-tumor activity in mouse models.</p>Formule :C25H30BrN7O2SCouleur et forme :SolidMasse moléculaire :572.52IGF-1R modulator 1
CAS :<p>IGF-1Rmodulator 1 (Example 5) is an IGF-1R modulator featuring an EC50 of 0.29 μM (FGFR1), 0.25 μM (IGF1R), 0.34 μM (TrkA), and 0.39 μM (TrkB). This compound is useful in research on diseases characterized by impaired signaling of neurotrophic and/or other trophic factors, such as Alzheimer's disease.</p>Formule :C22H17N3O4Couleur et forme :SolidMasse moléculaire :387.39EGFR-IN-109
CAS :<p>EGFR-IN-109 (compound 4), an EGFR inhibitor, displays IC 50 values of 25.8 nM for EGFR WT and 182.3 nM for EGFR T790M. This compound halts the growth of cancer cells at the G2/M phase and triggers both early and late apoptosis. It is applicable in cancer research [1].</p>Formule :C12H16N4OSCouleur et forme :SolidMasse moléculaire :264.35HVH-2930
CAS :<p>HVH-2930 is an inhibitor of Heat Shock Protein 90 (HSP90). It suppresses the cell viability of BT474 (Trastuzumab sensitive) and JIMT-1 (Trastuzumab resistant) by downregulating HSP90 client proteins such as HER2, p-HER2, AKT, p-AKT, cyclin D1, and survivin, with IC50 values of 6.86 μM and 4.42 μM, respectively. Additionally, HVH-2930 demonstrates antitumor efficacy in a mouse model and exhibits favorable pharmacokinetic properties in vivo.</p>Formule :C29H36N4O3Couleur et forme :SolidMasse moléculaire :488.62GZD856 formic
CAS :<p>GZD856 formic inhibits PDGFRα/β (IC50: 68.6, 136.6 nM) & Bcr-Abl (IC50: 19.9, 15.4 nM), with antitumor properties.</p>Formule :C30H29F3N6O3Couleur et forme :SolidMasse moléculaire :578.58AD1058
CAS :<p>AD1058 is a selective ATR inhibitor that crosses the blood-brain barrier with in vivo anticancer activity, used in the study of brain and CNS metastasis.</p>Formule :C19H20N6O3SDegré de pureté :98.24%Couleur et forme :SolidMasse moléculaire :412.47Tyrphostin AG 1478
CAS :Produit contrôlé<p>Applications Tyrphostin AG 1478 is a potent and selective inhibitor of EGFR.<br></p>Formule :C16H14ClN3O2Couleur et forme :NeatMasse moléculaire :315.75Pulsatilla Saponin D (90%)
CAS :Produit contrôlé<p>Applications Pulsatilla Saponin D shows antiangiogenic and antitumor activity.<br>References Sang-Won, H. et al.: Carcinogen., 34, 2156 (2013);<br></p>Formule :C47H76O17Degré de pureté :90%Couleur et forme :NeatMasse moléculaire :913.1Des-(4-(dimethylamino)-2-butenoyl)-Neratinib
CAS :Produit contrôlé<p>Applications 6-Amino-4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-7-ethoxyquinoline-3-carbonitrile, is used in the synthetic preparation of aminopropanamides which is used in irreversible inhibition of epidermal growth factor receptor (EGFR) for potential use in cancer therapy.<br>References Carmi, C., et al.: J. Med. Chem., 55, 2251 (2012)<br></p>Formule :C24H20ClN5O2Couleur et forme :NeatMasse moléculaire :445.9Atrasentan
CAS :Produit contrôlé<p>Applications Atrasentan is a selective antagonist of the endothelin-A (ETA) receptor and binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.<br>References Bax, W., et al.: Trends Pharmacol. Sci., 15, 379 (1994); Winn, M., et al.: J. Med. Chem., 39, 1039 (1996); Wu-Wong, J., et al.: J. Pharmacol. Exp. Ther., 281, 791 (1997);<br></p>Formule :C29H38N2O6Couleur et forme :Off-WhiteMasse moléculaire :510.62N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinamine
CAS :Produit contrôléFormule :C20H16FN5O3Couleur et forme :Light Yellow To YellowMasse moléculaire :393.374-Fmoc-3(R)-morpholinecarboxylic Acid
CAS :Produit contrôlé<p>Applications 4-Fmoc-3(R)-morpholinecarboxylic Acid is used to prepare 125I-labeled morpholine-containing RGD ligand of αvβ3 integrin as angiogenesis imaging probe.<br>References Bianchini, F., et al.: J. Med. Chem., 55, 5024 (2012)<br></p>Formule :C20H19NO5Couleur et forme :NeatMasse moléculaire :353.37Tyrphostin AG 112
CAS :Produit contrôlé<p>Applications Tyrphostin AG 112 is an EGFR inhibitor.<br></p>Formule :C13H8N4OCouleur et forme :NeatMasse moléculaire :236.232,3-Naphthalic Anhydride
CAS :Produit contrôlé<p>Stability Moisture Sensitive<br>Applications 2,3-Naphthalic anhydride is used as a reagent to synthesize analogues of Thalidomide (T338850), an inhibitor of tumour necrosis factor that was once abandoned because it caused birth defects, but is currently used as an inhibitor of angiogenesis in patients with multiple myeloma.<br>References D’Amato, R., et al.: Proc. Nat. Acad. Sci., 91, 4082 (1994); Ehrenpreis, E., et al.: Gastroenterology, 117, 1271 (1999); Parma, T., et al.: Nat. Med., 5, 582 (1999); Singhal, S., et al.: New Engl. J. Med., 341, 1565 (1999)<br></p>Formule :C12H6O3Couleur et forme :NeatMasse moléculaire :198.17Dehydrodivanillin (~90%, contains up to 10% unknown inorganics)
CAS :Formule :C16H14O6Couleur et forme :NeatMasse moléculaire :302.2792-Chloro-N-[4-(1-cyanocyclopentyl)phenyl]-3-pyridinecarboxamide
CAS :Produit contrôlé<p>Applications 2-Chloro-N-[4-(1-cyanocyclopentyl)phenyl]-3-pyridinecarboxamide is an intermediate Apatinib 25-N-Oxide (A726160), a metabolite of the antiangiogenic agent and selective VEGFR2 inhibitor Apatinib (A726150).<br></p>Formule :C18H16ClN3OCouleur et forme :NeatMasse moléculaire :325.79LB 42708
CAS :Produit contrôlé<p>Applications LB 42708 is a selective nonpeptidic Farnesyltransferase (FTase) inhibitor.LB42708 suppresses tumor growth and tumor angiogenesis in both xenograft tumor models of Ras-mutated HCT116 cells and its wild-type Caco-2 cells, indicating its potential application in the treatment of both Ras-mutated and wild type tumors.<br>References Kim, C., et. al.: Mol. Pharmacol., 78, 142 (2010)<br></p>Formule :C30H27BrN4O2Couleur et forme :NeatMasse moléculaire :555.46Bucillamine
CAS :<p>Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF.</p>Formule :C7H13NO3S2Degré de pureté :99.47%Couleur et forme :SolidMasse moléculaire :223.31E3330
CAS :<p>E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity.</p>Formule :C21H30O6Degré de pureté :99.52%Couleur et forme :SolidMasse moléculaire :378.46YLT192
CAS :<p>YLT192 is an orally active and bioavailable VEGFR2 inhibitor. It also has potent antiangiogenic activity and antitumor efficacy.</p>Formule :C21H19N3O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :377.39TGFBR1-IN-1
CAS :<p>TGFBR1-IN-1 is an inhibitor of ALK5 (IC50 of 10-100 nM).</p>Formule :C23H17N5O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :427.48Antiproliferative agent-30
CAS :<p>Antiproliferative agent-30 (Compound 8g) demonstrates broad-spectrum antiproliferative activity, with IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM against</p>Formule :C24H26N4O4Couleur et forme :SolidMasse moléculaire :434.49BTK-IN-24
CAS :<p>BTK-IN-24 is a Bruton's tyrosine kinase (BTK) inhibitor with potential anticancer activity, and it can be used in the study of myeloproliferative disorders.</p>Formule :C26H19F4N5O2Degré de pureté :99.61%Couleur et forme :SolidMasse moléculaire :509.46THS-044
CAS :<p>THS-044 (N-[2-Nitro-4-(Trifluoromethyl)phenyl]morpholin-4-Amine) binding stabilizes the HIF2α PAS-B folded state with a kd of 2 μM and regulates HIF2 activity</p>Formule :C11H12F3N3O3Degré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :291.23DMPQ dihydrochloride
CAS :<p>PDGFRβ inhibitor</p>Formule :C16H16Cl2N2O2Degré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :339.22EGFR-IN-68
CAS :<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Formule :C24H22N2OCouleur et forme :SolidMasse moléculaire :354.44FM19G11
CAS :<p>FM19G11 is an inhibitor of hypoxia inducible factor (HIF) α-subunit (IC50 = 80 nM in hypoxia induced luciferase assay).</p>Formule :C23H17N3O8Degré de pureté :99.70%Couleur et forme :SolidMasse moléculaire :463.4BKI-1369
CAS :<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Formule :C23H27N7OCouleur et forme :SolidMasse moléculaire :417.51ACP-5862
CAS :<p>ACP-5862, active metabolite of Acalabrutinib, is a BTK inhibitor with an IC50 of 5.0 nM.</p>Formule :C26H23N7O3Couleur et forme :SolidMasse moléculaire :481.51NSC114126
CAS :<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formule :C22H20O4Couleur et forme :SolidMasse moléculaire :348.39EGFR-IN-50
CAS :<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Formule :C24H26BrN3O4S2Couleur et forme :SolidMasse moléculaire :564.51FLT3-IN-15
CAS :<p>FLT3-IN-15 is an orally active and potent FLT3 inhibitor, capable of acting on FLT3 (IC50: 0.87 nM) and FLT3/D835Y (IC50: 0.32 nM).</p>Formule :C22H23ClFN5O2Couleur et forme :SolidMasse moléculaire :443.91ALK5-IN-30
CAS :<p>ALK5-IN-30 (EX-07) is a potent inhibitor of ALK with inhibitory effects on ALK5 (IC50< 10 nM) and TGFβ-R1 (IC50< 10 nM).</p>Formule :C24H25FN8Couleur et forme :SolidMasse moléculaire :444.51AG-183
CAS :<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Formule :C13H8N4O3Couleur et forme :Brown SolidMasse moléculaire :268.23NSC81111
CAS :<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Formule :C19H16O4Couleur et forme :SolidMasse moléculaire :308.33Naphazoline
CAS :<p>Naphazoline (Naphcon-a) is a sympathomimetic compound with marked alpha adrenergic activity.</p>Formule :C14H14N2Degré de pureté :99.79%Couleur et forme :White Crystalline Powder SolidMasse moléculaire :210.27CJ-2360
CAS :<p>CJ-2360 is a potent ALK inhibitor, effective on wild-type and various mutants, with IC50 values ranging from 2.2 to 8.9 nM, also targeting 468 kinases.</p>Formule :C27H30FN5O2Couleur et forme :SolidMasse moléculaire :475.56SJF620
CAS :<p>SJF620 is a potent degrader of PROTAC BTK(DC50 : 7.9 nM).</p>Formule :C41H44N8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :760.84Flonoltinib
CAS :<p>Flonoltinib (JAK2/FLT3-IN-1) is an orally active and efficient JAK2/FLT3 inhibitor with anti-cancer properties.</p>Formule :C25H34FN7ODegré de pureté :99.52%Couleur et forme :SolidMasse moléculaire :467.58J-1048
CAS :<p>J-1048, an activin receptor-like kinase 5 (ALK5) inhibitor, effectively suppresses TAA-induced liver fibrosis in mice through specific inhibition of the TGF-β/</p>Formule :C23H17FN6S2Couleur et forme :SolidMasse moléculaire :460.55BTK inhibitor 10
CAS :<p>BTK inhibitor 10, an oral drug from patent WO2018145525, may treat rheumatoid arthritis.</p>Formule :C25H23N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :441.48Peficitinib hydrochloride
CAS :<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Formule :C18H23ClN4O2Couleur et forme :SolidMasse moléculaire :362.86JAK-IN-20
CAS :<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Formule :C28H30FN7O2Couleur et forme :SolidMasse moléculaire :515.58TX-1918
CAS :<p>TX-1918, a tyrphostin, blocks eEF-2K to hinder HepG2, HCT116 cell growth.</p>Formule :C14H12O3Couleur et forme :SolidMasse moléculaire :228.24TK4b
CAS :<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Formule :C21H22N2O2Couleur et forme :SolidMasse moléculaire :334.41FLT3/ITD-IN-2
CAS :<p>FLT3/ITD-IN-2: Powerful FLT3/ITD, FLT3D835Y, and FLT3 inhibitor; hinders AML cell growth. IC50s: 0.3-1.0 nM.</p>Formule :C23H26F3N7O2Couleur et forme :SolidMasse moléculaire :489.49KL-1156
CAS :<p>KL-1156 is an NF-κB inhibitor. It is also a lipopolysaccharide (LPS)-induced nitric oxide production inhibitor.</p>Formule :C17H17NO4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :299.32DB07107
CAS :<p>DB07107 is a potent inhibitor of drug resistant T315I mutant Bcr-Abl tyrosine kinase and a potent Akt1 inhibitor (IC50: 360 nM).</p>Formule :C23H22N4ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :370.45PD180970
CAS :<p>PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit.</p>Formule :C21H15Cl2FN4ODegré de pureté :98.67%Couleur et forme :SolidMasse moléculaire :429.27T338C Src-IN-2
CAS :<p>T338C Src-IN-2: Potent c-Src T338C kinase inhibitor; IC50: 317 nM, T338C/V323A: 57 nM, T338C/V323S: 19 nM.</p>Formule :C17H18FN5ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :327.36TK4g
CAS :<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Formule :C19H19N3O4SCouleur et forme :SolidMasse moléculaire :385.44EGFR-IN-67
CAS :<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Formule :C18H17N3SCouleur et forme :SolidMasse moléculaire :307.41Squarunkin A hydrochloride
CAS :<p>Squarunkin A HCl inhibits UNC119-cargo binding, specifically blocks Src kinase activation, IC50=10 nm.</p>Formule :C25H33ClF3N5O4Couleur et forme :SoildMasse moléculaire :560.02JAK-2/3-IN-2
CAS :<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Formule :C19H19ClN2OSCouleur et forme :SolidMasse moléculaire :358.89JNJ-47117096 hydrochloride
CAS :<p>JNJ-47117096 hydrochloride is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM.</p>Formule :C21H23ClN4O2Couleur et forme :SolidMasse moléculaire :398.89c-ABL-IN-2
CAS :<p>C-ABL-IN-2 is a potent c-Abl protein inhibitor, promising for research in cancer and neurodegenerative diseases like ALS and PD.</p>Formule :C21H20N4OCouleur et forme :SolidMasse moléculaire :344.41MS 154N
CAS :<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Formule :C47H56ClFN8O8Couleur et forme :SolidMasse moléculaire :915.45Esuberaprost Sodium
CAS :<p>Famitinib (SHR1020), an oral drug, inhibits c-kit, VEGFR-2, and PDGFRβ (IC50: 2.3/4.7/6.6 nM) and triggers apoptosis in gastric cancer.</p>Formule :C23H27FN4O2Couleur et forme :SolidMasse moléculaire :410.48OD36 hydrochloride
CAS :<p>OD36 hydrochloride (OD-36 hydrochloride) is a potent RIPK2 inhibitor with an IC50 of 5.3 nM.OD36 hydrochloride is a macrocyclic inhibitor that binds efficiently</p>Formule :C16H16Cl2N4O2Degré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :367.23TYK2-IN-12
CAS :<p>TYK2-IN-12: selective oral TYK2 inhibitor (Ki: 0.51 nM), blocks IL-12-induced IFNγ; IC50: human 2.7 µM, mouse 7.0 µM, used for psoriasis research.</p>Formule :C24H20F2N4O2Couleur et forme :SolidMasse moléculaire :434.44PDE5-IN-3
CAS :<p>PDE5-IN-3: Inhibits PDE5 (1.57 nM), EGFR (5.827 μM), Wnt pathway (1286.96 ng/mL), induces apoptosis, and has antitumor effects.</p>Formule :C21H14BrN5O2Couleur et forme :SolidMasse moléculaire :448.27PDGFR-IN-1
CAS :<p>PDGFR-IN-1 is a platelet-derived growth factor receptor (PDGFR) inhibitor, strongly inhibiting PDGFRα and PDGFRβ, useful for studying solid tumors.</p>Formule :C25H30N8ODegré de pureté :99.13% - 99.49%Couleur et forme :SolidMasse moléculaire :458.56IHMT-TRK-284
CAS :<p>IHMT-TRK-284: Oral type II TRK inhibitor; targets TRKA, TRKB, TRKC (IC50s: 10.5, 0.7, 2.6 nM); selective and anti-tumor effective.</p>Formule :C25H27N7OSCouleur et forme :SolidMasse moléculaire :473.59FGFR3-IN-2
CAS :<p>FGFR3-IN-2 (compound 18b) is a potent and selective FGFR3 inhibitor that inhibits FGFR3 (IC50: 4.1 nM) and VEGFR2 (IC50: 570 nM).</p>Formule :C28H39N9O4SCouleur et forme :SolidMasse moléculaire :597.73CpCDPK1/TgCDPK1-IN-1
CAS :<p>CpCDPK1/TgCDPK1-IN-1 is a inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections.</p>Formule :C18H17N5Degré de pureté :99.61%Couleur et forme :SolidMasse moléculaire :303.36AG-370
CAS :<p>AG 370, an indole tyrphostin, functions as a powerful inhibitor of PDGF-induced mitogenesis, demonstrating an IC50 of 20 μM.</p>Formule :C15H9N5Couleur et forme :SolidMasse moléculaire :259.27
![Methyl 6-[[[(2-Chloroethyl)amino]carbonyl]amino]-6-deoxy-α-D-glucopyranoside](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTR%2Fthumb-webp%2FM304420.webp&w=3840&q=75)
![2-Chloro-N-[4-(1-cyanocyclopentyl)phenyl]-3-pyridinecarboxamide](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTR%2Fthumb-webp%2FC364965.webp&w=3840&q=75)
